Somatropin long-acting - OPKO Health

Drug Profile

Somatropin long-acting - OPKO Health

Alternative Names: hGH-CTP; Human growth hormone-CTP; Lagova; MOD-4023; PF-06836922

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Modigene
  • Developer OPKO Health
  • Class Biological proteins; Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 16 Jun 2017 Efficacy data from a phase III trial in Somatropin deficiency released by OPKO Health
  • 16 Jun 2017 OPKO Health plans a clinical trial for Somatropin deficiency (In children) in Japan
  • 16 Jun 2017 OPKO Health plans open-label extension trials for the phase III (In adults) and phase II (In children) trials for Somatropin deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top